Compositions, methods of use, and methods of treatment

1. A composition, comprising a beta-lactamase inhibitor selected from of the following structures:

wherein each W is independently selected from: O, NO, S, SO, CH 2 , NMe 2 , CHMe, C(Me) 2 , CF 2 , or SO 2 ;

wherein X and Y are independently selected from: O, NH, NO, NMe, NMe 2 , S, SO, SO 2 , CF 2 , C(═O), CH, N, CR2, (CH 2 ) n , where n=1 or 2, a bond, or CMe 2 or wherein X—Y is selected from: CH═CH, cyclopropyl, or (CH 2 ) n , where n=1 or 2;

wherein each R1 is independently selected from: H, a halogen, Me, iPr, tBu, or, optionally substituted aryl or heteroaryl;

wherein each R2 is independently selected from: H, a halogen CH 3 , an optionally substituted alkyl, or optionally substituted aryl or heteroaryl, OMe, NH 2 , N(Me) 2 , or an alkyl substituted amine;

wherein each R3 is independently selected from: H, aryl, thiophene, imidazole, pyrimidone, or optionally substituted aryl or heteroaryl, Me, iPr, tBu, or; aryl, thiophene, imidazole, pyrimidone;

wherein each R4 is independently selected from: H, Me, iPr, tBu, substituted and unsubstituted aryl or heteroaryl thiophene, imidazole, pyrimidone, acylated substituted and unsubstituted aryl or heteroaryl;

wherein each R5 is independently selected from: H, F, Me, iPr, tBu, optionally substituted aryl or heteroaryl, aryl, thiophene, imidazole, pyrimidone; and

wherein each R6 is independently selected from: H, Me, iPr, tBu, substituted or unsubstituted aryl or heteroaryl.

2. The composition of claim 1 , further comprising an antibiotic.

3. The composition of claim 2 , wherein the antibiotic is a beta-lactam antibiotic.

4. The composition of claim 1 , wherein beta-lactamase inhibitor is selected from one of the following structures:

wherein each W is independently selected from: 0, NO, 5, SO, or SO 2 ;

wherein each X is independently selected from: O, NH, NO, NMe, S, SO, SO 2 , C(═O), CF 2 , CMe 2 , or (CH 2 ) n , where n=1 or 2;

wherein each Y is independently selected from: CH, N, CR2, or NO;

wherein, each R1 is independently selected from H, Me, iPr, or tBu;

wherein each R2 is independently selected from: H, F, CH 3 , OMe, NH 2 , N(Me) 2 , or an alkyl substituted amine;

wherein each R3 is independently selected from: H, aryl, thiophene, imidazole, benzimidazole, pyrimidone, substituted aryl or heteroaryl, Me, iPr, or tBu;

wherein each R4 is independently selected from: H, Me, iPr, tBu, or substituted and unsubstituted aryl or heteroaryl; and

wherein each R5 is independently selected from: H, a halogen, F, Me, or substituted and unsubstituted aryl or heteroaryl.

5. The composition of claim 1 , wherein beta-lactamase inhibitor is selected from one of the following structures:

wherein each W is independently selected from: CH 2 , O, S, SO, SO 2 , NO, or NMe 2 ;

wherein each X is independently selected from: CH or N;

wherein each Y is independently selected from: O, S, SO, SO 2 , NH, NO, or NMe;

wherein each R1 is independently selected from: H, Me, iPr, or tBu;

wherein each R2 is independently selected from: aryl, thiophene, imidazole, pyrimidone, substituted and unsubstituted aryl or heteroaryl; Me, iPr, tBu, or pyrimidone;

wherein each R3 is independently selected from: aryl, thiophene, imidazole, pyrimidone, heteroaryl Me, iPr, tBu, thiophene, imidazole, pyrimidone, or substituted and unsubstituted aryl or heteroaryl;

wherein each R4 is independently selected from: aryl, thiophene, imidazole, pyrimidone, substituted and unsubstituted aryl or heteroaryl Me, iPr, tBu, thiophene, imidazole, pyrimidone or substituted and unsubstituted aryl or heteroaryl;

wherein each R5 is independently selected from: H, Me, iPr, tBu, or substituted and unsubstituted aryl or heteroaryl; and

wherein each R6 is independently selected from: H, F, Me, or substituted and unsubstituted aryl or heteroaryl.

6. The composition of claim 1 , wherein beta-lactamase inhibitor is selected from one of the following structures:

wherein each W is independently selected from: CH 2 , CHMe, C(Me) 2 , or CF 2 ;

wherein each X is independently a “bond” or (CH 2 ) n , where n=1 or 2;

wherein each Y is independently selected from CH, N, or NO;

wherein each R1 is independently selected from: H, Me, iPr, or tBu;

wherein each R2 is independently selected from: H, aryl, thiophene, imidazole, pyrimidone, Me, iPr, tBu, aryl, thiophene, imidazole, pyrimidone, or substituted and unsubstituted aryl or heteroaryl;

wherein each R3 is independently selected from: H, F, Me, or substituted and unsubstituted aryl or heteroaryl;

wherein each R4 is independently selected from: H, aryl, thiophene, imidazole, pyrimidone, or substituted and unsubstituted aryl or heteroaryl systems; Me, iPr, tBu, or thiophene, imidazole, pyrimidone;

wherein each R5 is independently selected from: aryl, thiophene, imidazole, pyrimidone, substituted and unsubstituted aryl or heteroaryl systems; Me, iPr, tBu, thiophene, imidazole, or pyrimidone; and

wherein each R6 is independently selected from: H, Me, iPr, tBu, or substituted and unsubstituted aryl or heteroaryl.

7. The composition of claim 1 , wherein beta-lactamase inhibitor is selected from one of the following structures:

wherein X and Y are independently selected from: O, NH, NO, NMe, NMe 2 , S, SO, SO 2 , CF 2 , CH 2 , or CMe 2 or wherein X—Y is selected from: CH═CH, cyclopropyl, or (CH 2 ) n , where n=1 or 2;

wherein each R1 is independently selected from: H, F, Me, or substituted and unsubstituted aryl or heteroaryl;

wherein each R2 is independently be selected from: H, Me, iPr, tBu, or substituted and unsubstituted aryl or heteroaryl; and

wherein each R3 is independently selected from: aryl, thiophene, imidazole, benzimidazole, pyrimidone, substituted and unsubstituted aryl or heteroaryl; Me, iPr, or tBu; and

wherein each R3 is independently selected from: aryl, thiophene, imidazole, benzimidazole, pyrimidone, substituted and unsubstituted aryl or heteroaryl; Me, iPr, tBu, thiophene, imidazole, benzimidazole, or pyrimidone.

8. The composition of claim 1 , wherein beta-lactamase inhibitor is selected from one of the following structures:

wherein each W is independently selected from: O, NO, S, SO, or SO 2 ;

wherein each R1 is independently selected from: H, Me, iPr, tBu, or other short aliphatic group, optionally substituted with F;

wherein each R2 is independently selected from: aryl, thiophene, imidazole, pyrimidone, substituted and unsubstituted aryl or heteroaryl systems; Me, iPr, or tBu;

wherein each R3 is independently selected from: aryl, thiophene, imidazole, pyrimidone, substituted and unsubstituted aryl or heteroaryl; Me, iPr, or tBu; and

wherein each R4 is independently selected from: H, Me, iPr, tBu, or substituted and unsubstituted aryl or heteroaryl.

9. A pharmaceutical composition comprising a therapeutically effective amount of a beta-lactamase inhibitor, or a pharmaceutically acceptable salt of the beta-lactamase inhibitor, and a pharmaceutically acceptable carrier, to treat a condition, wherein the beta-lactamase inhibitor has one of the following structures:

wherein each W is independently selected from: O, NO, S, SO, CH 2 , NMe 2 , CHMe, C(Me) 2 , CF 2 , or SO 2 ;

wherein X and Y are independently selected from: O, NH, NO, NMe, NMe 2 , S, SO, SO 2 , CF 2 , C(═O), CH, N, CR2, (CH 2 ) n , where n=1 or 2, a bond, or CMe 2 or wherein X—Y is selected from: CH═CH, cyclopropyl, or (CH 2 ) n , where n=1 or 2;

wherein each R1 is independently selected from: H, a halogen, Me, iPr, tBu, or, optionally substituted aryl or heteroaryl;

wherein each R2 is independently selected from: H, a halogen CH 3 , optionally substituted alkyl group, or optionally substituted aryl or heteroaryl group, OMe, NH 2 , N(Me) 2 , or an alkyl substituted amine;

wherein each R3 is independently selected from: H, aryl, thiophene, imidazole, pyrimidone, optionally substituted aryl or heteroaryl, Me, iPr, tBu, benzylic aryl, thiophene, imidazole, or pyrimidone;

wherein each R4 is independently selected from: H, Me, iPr, tBu, substituted and unsubstituted aryl or heteroaryl, aryl, thiophene, imidazole, or pyrimidone;

wherein each R5 is independently selected from: H, F, Me, iPr, tBu, optionally substituted aryl or heteroaryl, aryl, thiophene, imidazole, or; and

wherein each R6 is independently selected from: H, Me, iPr, tBu, and substituted or unsubstituted aryl or heteroaryl.

10. The pharmaceutical composition of claim 1 , further comprising an antibiotic.

11. The pharmaceutical composition of claim 10 , wherein the antibiotic is a beta-lactam antibiotic.

12. The pharmaceutical of claim 9 , wherein beta-lactamase inhibitor is selected from one of the following structures:

wherein each W is independently selected from: O, NO, S, SO, or SO 2 ;

wherein each X is independently selected from: O, NH, NO, NMe, S, SO, SO 2 , C(═O), CF 2 , CMe 2 , or (CH 2 ) n , where n=1 or 2;

wherein each Y is independently selected from: CH, N, CR2, or NO;

wherein, each R1 is independently selected from H, Me, iPr, or tBu;

wherein each R2 is independently selected from: H, F, CH 3 , OMe, NH 2 ; N(Me) 2 , or an alkyl substituted amine;

wherein each R3 is independently selected from: H, aryl, thiophene, imidazole, benzimidazole, pyrimidone, substituted aryl or heteroaryl, Me, iPr, or tBu;

wherein each R4 is independently selected from: H, Me, iPr, tBu, and substituted or unsubstituted aryl or heteroaryl; and

wherein each R5 is independently selected from: H, a halogen, F, Me, and substituted or unsubstituted aryl or heteroaryl.

13. The pharmaceutical of claim 9 , wherein beta-lactamase inhibitor is selected from one of the following structures:

wherein each W is independently selected from: CH 2 , O, S, SO, SO 2 , NO, or NMe 2 ;

wherein each X is independently selected from: CH or N;

wherein each Y is independently selected from: O, S, SO, SO 2 , NH, NO, or NMe;

wherein each R1 is independently selected from: H, Me, iPr, and tBu;

wherein each R2 is independently selected from: aryl, thiophene, imidazole, pyrimidone, substituted and unsubstituted aryl or heteroaryl; Me, iPr, tBu, thiophene, imidazole, and pyrimidone;

wherein each R3 is independently selected from: aryl, thiophene, imidazole, pyrimidone, substituted and unsubstituted aryl or heteroaryl systems; Me, iPr, tBu, thiophene, imidazole, or pyrimidone;

wherein each R4 is independently selected from: aryl, thiophene, imidazole, pyrimidone, substituted and unsubstituted aryl or heteroaryl systems; Me, iPr, tBu, thiophene, imidazole, pyrimidone;

wherein each R5 is independently selected from: H, Me, iPr, tBu, or substituted and unsubstituted aryl or heteroaryl systems; and

wherein each R6 is independently selected from: H, F, Me, or substituted and unsubstituted aryl or heteroaryl systems.

14. The pharmaceutical of claim 9 , wherein beta-lactamase inhibitor is selected from one of the following structures:

wherein each W is independently selected from: CH 2 , CHMe, C(Me) 2 , or CF 2 ;

wherein each X is independently a bond or (CH 2 ) n , where n=1 or 2;

wherein each Y is independently selected from CH, N, or NO;

wherein each R1 is independently selected from: H, Me, iPr, tBu, or other short aliphatic fluorocarbons;

wherein each R2 is independently selected from: H, aryl, thiophene, imidazole, pyrimidone, substituted and unsubstituted aryl or heteroaryl; Me, iPr, tBu, thiophene, imidazole, or pyrimidone;

wherein each R3 is independently selected from: H, F, Me, or substituted and unsubstituted aryl or heteroaryl;

wherein each R4 is independently selected from: H, aryl, thiophene, imidazole, pyrimidone, substituted and unsubstituted aryl or heteroaryl; Me, iPr, tBu, thiophene, imidazole, or pyrimidone;

wherein each R5 is independently selected from: aryl, thiophene, imidazole, pyrimidone, substituted and unsubstituted aryl or heteroaryl;

Me, iPr, tBu, thiophene, imidazole, or pyrimidone; and

wherein each R6 is independently selected from: H, Me, iPr, tBu, or substituted and unsubstituted aryl or heteroaryl.

15. The pharmaceutical of claim 9 , wherein beta-lactamase inhibitor is selected from one of the following structures:

wherein X and Y are independently selected from: O, NH, NO, NMe, NMe 2 , S, SO, SO 2 , CF 2 , CH 2 , or CMe 2 or wherein X—Y is selected from: CH═CH, cyclopropyl, or (CH 2 ) n , where n=1 or 2;

wherein each R1 is independently selected from: H, F, Me, or substituted and unsubstituted aryl or heteroaryl;

wherein each R2 is independently be selected from: H, Me, iPr, tBu, substituted and unsubstituted aryl or heteroaryl; and

wherein each R3 is independently selected from: aryl, thiophene, imidazole, benzimidazole, pyrimidone, substituted and unsubstituted aryl or heteroaryl; Me, iPr, or tBu; and

wherein each R3 is independently selected from: aryl, thiophene, imidazole, benzimidazole, pyrimidone, substituted and unsubstituted aryl or heteroaryl; Me, iPr, tBu, thiophene, imidazole, benzimidazole, or pyrimidone.

16. The pharmaceutical of claim 9 , wherein beta-lactamase inhibitor is selected from one of the following structures:

wherein each W is independently selected from: O, NO, S, SO, or SO 2 ;

wherein each R1 is independently selected from: H, Me, iPr, or tBu;

wherein each R2 is independently selected from: aryl, thiophene, imidazole, pyrimidone, substituted and unsubstituted aryl or heteroaryl; Me, iPr, or tBu;

wherein each R3 is independently selected from: aryl, thiophene, imidazole, pyrimidone, substituted and unsubstituted aryl or heteroaryl; Me, iPr, or tBu; and

wherein each R4 is independently selected from: H, Me, iPr, tBu, or substituted and unsubstituted aryl or heteroaryl.